Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 4.40
BCRX's Cash to Debt is ranked higher than
68% of the 904 Companies
in the Global Biotechnology industry.

( Industry Median: 42.14 vs. BCRX: 4.40 )
BCRX' s 10-Year Cash to Debt Range
Min: 0.94   Max: 11087.67
Current: 4.4

0.94
11087.67
Equity to Asset 0.64
BCRX's Equity to Asset is ranked higher than
72% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. BCRX: 0.64 )
BCRX' s 10-Year Equity to Asset Range
Min: -0.23   Max: 0.98
Current: 0.64

-0.23
0.98
F-Score: 5
Z-Score: 6.81
M-Score: -2.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -177.24
BCRX's Operating margin (%) is ranked higher than
65% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. BCRX: -177.24 )
BCRX' s 10-Year Operating margin (%) Range
Min: -17879.61   Max: -18.42
Current: -177.24

-17879.61
-18.42
Net-margin (%) -173.72
BCRX's Net-margin (%) is ranked higher than
65% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. BCRX: -173.72 )
BCRX' s 10-Year Net-margin (%) Range
Min: -17170.39   Max: -18.03
Current: -173.72

-17170.39
-18.03
ROA (%) -61.61
BCRX's ROA (%) is ranked higher than
58% of the 904 Companies
in the Global Biotechnology industry.

( Industry Median: -17.94 vs. BCRX: -61.61 )
BCRX' s 10-Year ROA (%) Range
Min: -69.27   Max: -7.22
Current: -61.61

-69.27
-7.22
ROC (Joel Greenblatt) (%) -10038.24
BCRX's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 881 Companies
in the Global Biotechnology industry.

( Industry Median: -200.53 vs. BCRX: -10038.24 )
BCRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -10038.24   Max: -31.15
Current: -10038.24

-10038.24
-31.15
Revenue Growth (%) -39.50
BCRX's Revenue Growth (%) is ranked higher than
61% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. BCRX: -39.50 )
BCRX' s 10-Year Revenue Growth (%) Range
Min: -68.5   Max: 430.1
Current: -39.5

-68.5
430.1
EBITDA Growth (%) -14.50
BCRX's EBITDA Growth (%) is ranked higher than
70% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. BCRX: -14.50 )
BCRX' s 10-Year EBITDA Growth (%) Range
Min: -41.9   Max: 64.5
Current: -14.5

-41.9
64.5
EPS Growth (%) -10.20
BCRX's EPS Growth (%) is ranked higher than
76% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: -12.20 vs. BCRX: -10.20 )
BCRX' s 10-Year EPS Growth (%) Range
Min: -38.4   Max: 52.9
Current: -10.2

-38.4
52.9
» BCRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2012

BCRX Guru Trades in Q3 2012

Jim Simons 70,129 sh (-52.93%)
» More
Q4 2012

BCRX Guru Trades in Q4 2012

Jim Simons Sold Out
» More
Q1 2014

BCRX Guru Trades in Q1 2014

George Soros 59,700 sh (New)
Jim Simons 90,514 sh (New)
» More
Q2 2014

BCRX Guru Trades in Q2 2014

George Soros Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BCRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 Sold Out 0.01%$7.37 - $12.52 $ 13.6341%0
George Soros 2014-03-31 New Buy0.01%$7.6 - $12.83 $ 13.6329%59700
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.09
BCRX's P/B is ranked higher than
52% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 6.10 vs. BCRX: 9.09 )
BCRX' s 10-Year P/B Range
Min: 1.04   Max: 122.5
Current: 9.09

1.04
122.5
P/S 45.66
BCRX's P/S is ranked higher than
51% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 19.49 vs. BCRX: 45.66 )
BCRX' s 10-Year P/S Range
Min: 0.73   Max: 2000
Current: 45.66

0.73
2000
EV-to-EBIT -25.32
BCRX's EV-to-EBIT is ranked higher than
72% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BCRX: -25.32 )
BCRX' s 10-Year EV-to-EBIT Range
Min: 0.3   Max: 1473.6
Current: -25.32

0.3
1473.6
Current Ratio 3.08
BCRX's Current Ratio is ranked higher than
67% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.29 vs. BCRX: 3.08 )
BCRX' s 10-Year Current Ratio Range
Min: 2.01   Max: 39.53
Current: 3.08

2.01
39.53
Quick Ratio 3.08
BCRX's Quick Ratio is ranked higher than
69% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 3.87 vs. BCRX: 3.08 )
BCRX' s 10-Year Quick Ratio Range
Min: 2   Max: 39.53
Current: 3.08

2
39.53

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.17
BCRX's Price/Net Cash is ranked higher than
86% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 965.00 vs. BCRX: 10.17 )
BCRX' s 10-Year Price/Net Cash Range
Min: 0.61   Max: 315
Current: 10.17

0.61
315
Price/Net Current Asset Value 10.09
BCRX's Price/Net Current Asset Value is ranked higher than
85% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 217.00 vs. BCRX: 10.09 )
BCRX' s 10-Year Price/Net Current Asset Value Range
Min: 0.61   Max: 191
Current: 10.09

0.61
191
Price/Tangible Book 9.09
BCRX's Price/Tangible Book is ranked higher than
72% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9.20 vs. BCRX: 9.09 )
BCRX' s 10-Year Price/Tangible Book Range
Min: 0.33   Max: 121.33
Current: 9.09

0.33
121.33
Price/Median PS Value 5.95
BCRX's Price/Median PS Value is ranked higher than
66% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 1.94 vs. BCRX: 5.95 )
BCRX' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 122.25
Current: 5.95

0.12
122.25
Earnings Yield (Greenblatt) 36.90
BCRX's Earnings Yield (Greenblatt) is ranked higher than
84% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. BCRX: 36.90 )
BCRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 355.1
Current: 36.9

0.1
355.1
Forward Rate of Return (Yacktman) 13.07
BCRX's Forward Rate of Return (Yacktman) is ranked higher than
94% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: -9.52 vs. BCRX: 13.07 )
BCRX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -54.7   Max: -27.4
Current: 13.07

-54.7
-27.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BO1.Germany
BioCryst Pharmaceuticals is a Delaware Corporation originally founded in 1986. The Company is a biotechnology company that designs, optimizes and develops novel drugs that block key enzymes involved in cancer, viral infections and autoimmune diseases. BioCryst integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-based drug design. Structure-guided drug design is a drug discovery approach by which it designs synthetic compounds from detailed structural knowledge of the active sites of enzyme targets associated with particular diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company has two Purine Nucleoside Phosphorylase (PNP ) inhibitors that are in development, ulodesine for the treatment of gout and forodesine for the treatment of hematological malignancies. PNP is a purine salvage pathway enzyme. Low doses of PNP inhibitors could be useful in reducing serum uric acid for the treatment of gout, while high doses of PNP inhibitors could be useful in the treatment of hematological malignancies. The FDA regulates the pharmaceutical and biotechnology industries in the U.S., and its drug candidates are subject to extensive and rigorous domestic government regulations prior to commercialization.
» More Articles for BCRX

Headlines

Articles On GuruFocus.com
comment on BCRX Mar 02 2013 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K/A) Jan 19 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 2,500 Shares Aug 06 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares Jun 04 2010 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares May 05 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 38,553 Shares Apr 30 2010 

More From Other Websites
Nasdaq stocks posting largest percentage increases Aug 27 2014
How Will We Know If The Ebola Drugs Worked? Aug 26 2014
BIOCRYST PHARMACEUTICALS INC Financials Aug 15 2014
BioCryst Receives Additional NIAID Funding to Advance Development of BCX4430 to Treat Hemorrhagic... Aug 13 2014
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Aug 13 2014
BioCryst Receives Additional NIAID Funding to Advance Development of BCX4430 to Treat Hemorrhagic... Aug 13 2014
WHO backs use of experimental Ebola drugs in West Africa Aug 12 2014
WHO backs use of experimental Ebola drugs in West Africa Aug 12 2014
Tekmira Shares Continue to Rise in the Search for Ebola Cure Aug 12 2014
WHO backs use of experimental Ebola drugs in West Africa outbreak Aug 12 2014
WHO backs use of experimental Ebola drugs in West Africa outbreak Aug 12 2014
Tekmira Pharma Soars on FDA Announcement over Ebola Drug Aug 11 2014
BIOCRYST PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 08 2014
Ebola drug maker's shares soar as FDA opens door to treatment use Aug 08 2014
Will This Coverage Initiation Help BioCryst Pharmaceuticals (BCRX) Stock Today? Aug 08 2014
Looking to trade on Ebola? Beware Aug 07 2014
MLV & Co Sees Positive Momentum Going Into 2H14 For BioCryst Pharmaceuticals Aug 07 2014
Ebola Drug Panel Set by WHO to Weigh Unproven Drugs Use Aug 06 2014
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Capital One Financial, Principal Financial... Aug 06 2014
Can the Uptrend Continue for BioCryst (BCRX)? Aug 06 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK